NewsRoom Articles - Page 59 of 154 - PsychedelicNewsWire (PNW)

WednesdayMay 18, 2022 1:48 pm

Senators Want Federal Agencies to Review Psychedelic Research

Senators Cory Booker and Brian Schatz are calling for federal agencies to provide updates on studies into the therapeutic potential of psychedelic substances. In a letter penned to the top officials at the FDA and the National Institutes on Health, the senators stated that the agencies were crucial to ensuring a rigorous and comprehensive science-based approach to research on psychedelics. The senators stated that they are encouraged that the National Institutes of Health held a workshop earlier this year to look into the regulatory challenges that are hindering research into psychedelic substances, including MDMA and psilocybin. The senators, who argued…

TuesdayMay 17, 2022 3:48 pm

First Psychedelic Trial Clinic Set to Launch in London

Clerkenwell Health, a start-up based in the United Kingdom, plans to open a commercial facility for carrying out drug trials on psychedelics in London. This facility will be the first in Europe to be launched for this particular purpose. The company plans to start trials that will focus on the potential for psychedelic drugs in treating mental health conditions, including end-of-life anxiety, nicotine dependency and post-traumatic stress disorder, by August. In a recent interview, Clerkenwell Health CEO Tom McDonald stated that the United Kingdom was well positioned to be at the forefront of psychedelic-assisted therapy as a global leader in…

TuesdayMay 17, 2022 9:45 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Capitalizing on Psychedelics Drug Market, with 13 Wellness Clinics Across Nine States and Growing

Delic Holdings Corp. comprises several businesses—Delic Labs, Meet Delic, and Ketamine Wellness Centers and media properties Reality Sandwich and Delic Radio The psychedelic drugs market is expected to reach US $9,818.68 million by 2029 – primarily driven by an increase in acceptance for use in mental health The company’s goal is to expand its clinic offering to 60-70% of the American population driving no more than 45-minutes to reach a clinic Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, is committed to bringing the science-backed benefits of psychedelics to more people…

MondayMay 16, 2022 3:58 pm

Takeaways from Benzinga’s Psychedelics Capital Conference

Last month, Benzinga held its second Psychedelics Capital Conference in Miami Beach. The conference brought together investors, panelists, curious individuals and leaders of major publicly traded psychedelic firms. Below are a few takeaways from the psychedelics conference. Irwin Naturals plans to become a major specialty brand in mental health Klee Irwin, CEO and founder of Irwin Naturals, stated during his keynote session that the company was focused on leveraging its profitable premium supplement and vitamin business and its household name to become the biggest specialty brand of psychedelic mental health clinics. This keynote session and others from individuals and companies…

FridayMay 13, 2022 2:31 pm

Wesana Health Could Divest Itself of All Assets Except Drug-Development Unit

Last week, Wesana Health announced that it was considering selling its assets under the division focused on care delivery, which includes its psychedelic therapy clinics. In its press release, the integrated life science company stated that it was planning to focus on its drug-development division. Before making this announcement, the company was focused on the development of new therapies and delivering new care. Wesana Health is now considering selling its communication platform for psychedelic practitioners, known as PsyTech Connect, and its platform, which was designed to improve clinical protocols, known as Wesana Solutions. This is in addition to plans to…

ThursdayMay 12, 2022 1:55 pm

Compass Pathways Research Suggests Psilocybin Can Treat Anorexia

Recently released findings from a study show that the psilocybin therapy developed by Compass Pathways PLC (NASDAQ: CMPS) may be used to treat anorexia. The therapy in question, COMP 360, was primarily developed to treat depression. Anorexia or anorexia nervosa is an eating disorder in which individuals have abnormally low weight caused by restricting food intake and an extreme fear of gaining weight. Psychiatrist Katherine A. Halmi believes that this eating disorder stems from the ego, explaining that the severity of the core features of the disorder, including preoccupations with exercising, eating, weight and body image, forecast higher resistance to…

WednesdayMay 11, 2022 11:57 am

Study Indicates People Are Cautious About Psilocybin Therapy, More Awareness Needed

A new study has found that individuals are cautious about the use of psilocybin-assisted psychotherapy in the treatment of depression. Psilocybin is an active chemical found in magic mushrooms. This mind-altering compound may influence how individuals experience the world by inducing changes in the sense of self as well as a user’s perception of time, sensory perception and mood. Preliminary studies have shown that administering psilocybin in conjunction with psychotherapy can bring about improvements for patients afflicted by depression. The researchers’ objective was to look into individuals’ perceptions of psilocybin-assisted therapy in comparison to their perceptions of cognitive-behavioral therapy, which…

WednesdayMay 11, 2022 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3)…

TuesdayMay 10, 2022 3:27 pm

Survey Discovers That Psilocybin Is Relatively Safe Drug

Findings from a large survey propose that psilocybin is a relatively safe drug, with less than 1% of users of psilocybin mushrooms seeking emergency medical care after consumption. The survey’s findings, which also propose that adverse incidents resulting in emergency medical care are often psychological in nature and can be resolved in 24 hours, were reported in the “Journal of Psychopharmacology.” Psilocybin, which is the active ingredient found in hallucinogenic mushrooms, is known to induce a mind-altering state when consumed. While this compound is considered safe in comparison to other psychoactive substances, it can still cause adverse reactions such as…

MondayMay 09, 2022 1:52 pm

3 Psychedelic Documentaries You Can Watch on YouTube

New articles on psychedelic substances and their numerous uses in the field of medicine are being published every day in different parts of the world. As researchers discover more about psychedelics and the numerous benefits they hold, interest in these substances is growing. If you aren’t keen on reading medical journals to learn more about psychedelics but you’d still like to know more, here are some psychedelic documentaries you can watch on YouTube. True Hallucinations This experimental film, which is almost three hours long, is a tribute to the late philosopher Terence McKenna. McKenna spoke on and wrote about various…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000